Syncope, Brugada syndrome, and COVID‐19 lung disease

Pasquetto, Giampaolo; Conti, Giovanni Battista; Susana, Angela; Leone, Lucia; Bertaglia, Emanuele

doi:10.1002/joa3.12375

Cited by 12 publications

(16 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Out of the 8 case reports, syncope was the reason that prompted the visit to the Emergency Department in 7 of them (87.5%). (8) (10) (11) (12) (13) (14) (15) Furthermore, Ebrille et al (6) and Canetta et al (19) also described syncope as the presenting symptom of the infection. On the other hand, Argenziano et al .…”

Section: Resultsmentioning

confidence: 99%

“…Of the 19 included articles, 8 were case reports (8) (9) (10) (11) (12) (13) (14) (15), 6 were retrospective analyses (3) (7) (16) (17) (18) (19), 3 were case-series (6) (20) (21) and 2 were prospective studies (22) (23). Given the nature of the topic at hand, every article was published in 2020.…”

Section: Resultsmentioning

confidence: 99%

“…The majority of studies, 8, described syncopal episodes of unspecified etiology. (3) (7) (16) (17) (18) (21) (22) (23) Six studies attributed the cause to orthostatic hypotension (3) (6) (8) (12) (14) (15), while another 5 studies alluded to possible cardiac syncope (3) (9) (10) (11) (13). In turn, reflex syncope was highlighted in 4 of the studies.…”

Section: Resultsmentioning

confidence: 99%

“…Considering confirmed or presumable cardiac syncope, the 5 reported cases included situations of myocarditis (11), massive pulmonary embolism (PE) and ventricular fibrillation (9), Brugada Syndrome (13) (10) and new onset atrial fibrillation together with anterior wall ST elevation MI (3) as the underlying conditions.…”

Section: Resultsmentioning

confidence: 99%

“…(9) The overall prevalence of venous thromboembolism in the setting of COVID-19 is poorly defined, with current case series suggesting an approximate value between 20.6–25%. (27) Regarding Brugada syndrome, two patients (10, 13) presented with syncope, fever and Brugada pattern on the 12-lead ECG, which led to the diagnosis of this syndrome and resulted in the implantation of a subcutaneous implantable cardioverter defibrillator (S-ICD) in one patient and use of a wearable cardioverter defibrillator in the other. Fever is known to unmask Brugada’s ECG pattern and to precipitate ventricular arrhythmias in these patients and one study showed that more than half of the study cohort experienced syncope or cardiac arrest in the setting of a fever (28).…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Syncope and COVID-19 disease – a systematic review

Freitas

Torres

Nunes

2021

Preprint

View full text Add to dashboard Cite

BackgroundSyncope is not a common manifestation of COVID-19, but it may occur in this context and it can be the presenting symptom in some cases. Although several mechanisms may explain the pathophysiology behind COVID-19 related syncope, a valid relationship has not been established yet. In this systematic review, we aimed to examine the current incidence of syncope in COVID-19 patients and to explore different patterns observed in this setting.MethodsA systematic review across PubMed, ISI Web of Knowledge and SCOPUS was performed, according to PRISMA guidelines, in order to identify all relevant articles regarding both COVID-19 and syncope.ResultsWe identified 81 publications, of which 62 were excluded. The cumulative incidence of syncope and pre-syncope across the selected studies was 7.1% (256/3584 patients). Unspecified syncope was the most common type (76.2% of the reported episodes), followed by reflex syncope (18.1% of the cases). Orthostatic hypotension was responsible for 3.6% of the cases and syncope of presumable cardiac cause accounted for 2.0%. Arterial hypertension was present in 64.7% of the patients and either angiotensin receptor blockers or angiotensin converting enzyme inhibitors were used by 39.5% of hypertensive patients with syncope.ConclusionSyncope, although not considered a typical symptom of the COVID-19 disease, can be associated with it, particularly in early stages. Different types of syncope were seen in this context, each with different implications requiring distinct approaches. A careful reevaluation of blood pressure whenever a patient develops COVID-19 is suggested, including reassessment of antihypertensive therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Syncope and COVID-19 disease – a systematic review

Freitas

Torres

Nunes

2021

Preprint

View full text Add to dashboard Cite

show abstract

Syncope and COVID-19 disease – A systematic review

Freitas

Torres

Martín‐Sánchez

et al. 2021

Autonomic Neuroscience

View full text Add to dashboard Cite

Background: Syncope is not a common manifestation of COVID-19, but it may occur in this context and it can be the presenting symptom in some cases. Different mechanisms may explain the pathophysiology behind COVID-19 related syncope. In this report, we aimed to examine the current frequency and etiology of syncope in COVID-19. Methods: A systematic review across PubMed, ISI Web of Knowledge and SCOPUS was performed, according to PRISMA guidelines, in order to identify all relevant articles regarding both COVID-19 and syncope. Results: We identified 136 publications, of which 99 were excluded. The frequency of syncope and pre-syncope across the selected studies was 4.2% (604/14,437). Unexplained syncope was the most common type (87.9% of the episodes), followed by reflex syncope (7.8% of the cases). Orthostatic hypotension was responsible for 2.2% of the cases and syncope of presumable cardiac cause also accounted for 2.2% of cases. Arterial hypertension was present in 52.0% of syncope patients. The use of angiotensin receptor blockers or angiotensin converting enzyme inhibitors were not associated with an increased incidence of syncope (chi-square test 1.07, p 0.30), unlike the use of beta-blockers (chi-square test 12.48, p < 0.01). Conclusion: Syncope, although not considered a typical symptom of COVID-19, can be associated with it, particularly in early stages. Different causes of syncope were seen in this context. A reevaluation of blood pressure in patients with COVID-19 is suggested, including reassessment of antihypertensive therapy, especially in the case of beta-blockers.

show abstract

Arrhythmias in the COVID-19 patient

Lavelle¹,

Desai²,

Wan

2022

Heart Rhythm O2

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has encompassed the globe since it was first observed just under 2 years ago. Although the disease is predominantly a respiratory illness, there have been observed complications throughout the various organ systems. Namely, cardiovascular complications, and, more specifically, arrhythmic complications have been described throughout the pandemic in patients with COVID-19. Management of atrial arrhythmias, ventricular arrhythmias, and bradyarrhythmias in patients with COVID-19 infection has been largely guided by our prior experience in the management of these arrhythmias in similar patient populations without infection. However, this review aims to highlight the specific considerations as they pertain to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the various arrhythmic manifestations observed with this disease.

show abstract

Syncope, Brugada syndrome, and COVID‐19 lung disease

Cited by 12 publications

References 4 publications

Syncope and COVID-19 disease – a systematic review

Syncope and COVID-19 disease – a systematic review

Syncope and COVID-19 disease – A systematic review

Arrhythmias in the COVID-19 patient

Contact Info

Product

Resources

About